Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Van der Westhuizen 2015 Abstract MiPschool Cape Town 2015"

From Bioblast
Line 1: Line 1:
{{Abstract
{{Abstract
|title=Investigating mitochondrial disorders in the South African context: meeting diversity with modern-day science.
|title=Investigating mitochondrial disorders in the South African context: meeting diversity with modern-day science.
|authors=van der Westhuizen FH
|authors=van der Westhuizen FH, Louw R, Smuts I
|year=2015
|year=2015
|event=MiPschool Cape Town 2015
|event=MiPschool Cape Town 2015

Revision as of 09:56, 10 February 2015

Investigating mitochondrial disorders in the South African context: meeting diversity with modern-day science.

Link:

van der Westhuizen FH, Louw R, Smuts I (2015)

Event: MiPschool Cape Town 2015

Disorders of energy metabolism are the largest group of rare diseases in humans and are caused by mtDNA and nDNA mutations in more than 240 genes. Amongst these genetic and phenotypic highly diverse disorders, mitochondrial respiratory chain disease (RCD) has an estimated prevalence of ~1:5000 in populations worldwide. Although research, diagnostics and more recently also therapies receives a lot of attention in developed countries, this has not been the case in Africa. We have approached the identification and characterization of these disorders as a multidisciplinary research project since 1998, focusing on RCD in paediatric patients of predominantly the northern provinces of South Africa. Some of the key features that shaped the trajectory of this study have been the population diversity in Southern Africa, demographic, socio-economic and health system constraints, as well as limited genetic information of the indigenous African populations. From a total patient group of of ~6000 new referrals to the paediatric neurology clinic at mainly the Steve Biko Academic Hospital (Pretoria) since 2006, a current study cohort of ~200 paediatric cases (61% African, 32% Caucasian, 7% other) with clinical scoring criteria suggestive of mitochondrial involvement had undergone a required muscle biopsy for further investigations. Over time, these cases had undergone extensive enzymology with ~65% showing a single or combined respiratory chain enzyme deficiency. Functional investigations, metabolomics and molecular genetics investigations were also conducted with the objectives of 1) accurate diagnosis, 2) identifying a urine metabolic biosignature (i.e. combination of metabolites) to improve case selection and 3) investigating the aetiology of these disorders. Within the investigations done over the past decade, we had used investigations, such as respiratory chain enzyme kinetics, respirometry and proteomics; as well as novel and high end technologies such as targeted and untargeted metabolomics, and various next generation sequencing applications for mtDNA and nuclear gene panel sequencing. From these investigations the key findings were: Firstly, looking at the phenotype, muscle involvement was more prevalent in patients of African descent, compared to Caucasian patients. Secondly, we were able to identify a metabolic biosignature in urine, which promises to greatly assist in the selection criteria for patients in line to undergo muscle biopsies. Finally, from current molecular genetic data, the prevalence of mtDNA mutations is significantly lower.


Labels: MiParea: Respiration, Instruments;methods, mtDNA;mt-genetics, mt-Medicine, Patients 







Affiliations

Biochemistry, Centre for Human Metabonomics, North-West Univ, South Africa. - [email protected]